Breaking News

Cerbios Names TAM COO

By Gil Roth | January 13, 2014

Will lead newly created Commercial Business Unit

Andrea Tam has been appointed chief commercial officer of Cerbios-Pharma SA. Mr. Tam will lead the newly created Commercial Business Unit, which includes the Chemical and Biological divisions.

The four teams that previously reported directly to the chief executive officer -- two Business Development and two Marketing & Sales -- will now report to Mr. Tam. In his new role he will be responsible for all commercial activities, from early stage to commercial supply, as well as customer services. Mr. Tam will report directly to chief executive officer Gabriel Haering and will continue his current activities as director Business Development.
“This structural change was required due to company growth and the increasing complexity of commercial relations in the different geographic areas where Cerbios is active,” said Mr. Haering. “This is also part of the long-term organizational strategy of Cerbios, that integrates all our activities in a leaner structure, creating value for our partners.”
Mr. Tam has been active in the pharmaceutical industry since 1998. In 2000 he joined the Italian subsidiary of Mitsubishi Chemical Corporation Group as R&D scientist achieving the position of R&D manager. In 2005, he joined Antibioticos Marketing & Sales Department, managing special projects and custom projects with key accounts. From 2007 to 2012 he served at Recordati S.p.A. as manager Business Development in the Pharmaceutical Chemicals Division, with world-wide responsibility, and then as BD Manager at Farmabios. He joined Cerbios in 2012 as director Business Development, taking care of Cerbios’ contract manufacturing activities.

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important